Brinker Capital Investments’s Protagonist Therapeutics PTGX Stock Holding History

Brinker Capital Investments’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$788K	Buy	6,428 +21	+0.3%	+$2.19K	0.01%	1284
2026 Q1	$675K	Buy	6,407 +2,011	+46%	+$178K	0.01%	1335
2025 Q4	$384K	Sell	4,396 -2,532	-37%	-$207K	﹤0.01%	1696
2025 Q3	$460K	Buy	6,928 +328	+5%	+$18.6K	﹤0.01%	1582
2025 Q2	$365K	Sell	6,600 -131	-2%	-$6.29K	﹤0.01%	1625
2025 Q1	$326K	Buy	+6,731	New	+$282K	﹤0.01%	1590
2024 Q4	–	Sell	-6,114	Closed	-$275K	–	1891
2024 Q3	$275K	Sell	6,114 -1,274	-17%	-$51.5K	﹤0.01%	1553
2024 Q2	$256K	Buy	+7,388	New	+$216K	﹤0.01%	1528

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Brinker Capital Investments's PTGX Position: Q2 2026 in Review

Brinker Capital Investments increased its Protagonist Therapeutics (PTGX) stake by 0.33% in Q2 2026, buying an estimated $2.19K and bringing the position to 6,428 shares worth $788K. The position accounts for 0.01% of the portfolio, ranked #1284.

Brinker Capital Investments first reported a position in PTGX in Q2 2024 and has held it in 8 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Brinker Capital Investments held 6,428 shares of Protagonist Therapeutics worth $788K as of Q2 2026.
Brinker Capital Investments bought 21 Protagonist Therapeutics shares in Q2 2026, an estimated $2.19K.
Protagonist Therapeutics made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1284 holding.
Brinker Capital Investments first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 8 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.